A review of neuraminidase inhibitor susceptibility in influenza strains

References

• Lamb R, Krug R. Orthomyxoviridae: the viruses and their replication. In: Fields B, Knipe D, Howley P, editors. Fields virology. Lippincott-Raven; Philadelphia, PA, USA: 1996
   Google Scholar
• Centers for Disease Control and Prevention. Influenza type A. viruses and subtypes. 2013; Retrieved 13 June 2013
   Google Scholar
• Gewin V. Bats harbour influenza. Nature 2012
   Google Scholar
• Tong S, Zhu X, Li Y, et al. New world bats harbor diverse influenza A viruses. PLoS Pathog 2013;9(10):e1003657
   PubMed Web of Science ®Google Scholar
• Krumbholz A, Schmidtke M, Bergmann S, et al. High prevalence of amantadine resistance among circulating European porcine influenza A viruses. J Gen Virol 2009;90(Pt 4):900-8
   PubMedGoogle Scholar
• Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009;325(5937):197-201
   PubMed Web of Science ®Google Scholar
• World Health Organization. State of the Art of Vaccine Research and Development. Geneva: world Health Organization; 2005. Available from: www.who.int/vaccine_research/documents/Dip%20814.pdf [Last accessed 17 February 2012]
   Google Scholar
• Nair H, Brooks WA, Katz M, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet 2011;378:1917-30
   PubMed Web of Science ®Google Scholar
• Pizzorno A, Bouhy X, Abed Y, Boivin G. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J Infect Dis 2011;203(1):25-31
   PubMed Web of Science ®Google Scholar
• Bright RA, Medina MJ, Xu X, et al. Incidence of adamantine resistance among influenza A(H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005;366:1175-81
   PubMed Web of Science ®Google Scholar
• CDC. Influenza flu. Available from: www.antimicrobe.org/h04c.files/history/cdc-flu.pdf
   Google Scholar
• Pizzorno A, Abed Y, Boivin G. Influenza drug resistance. Semin Respir Crit Care Med 2011;32:409-22
   PubMed Web of Science ®Google Scholar
• Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005;353:1363-73
   PubMed Web of Science ®Google Scholar
• Schulman JL, Palese P. Susceptibility of different strains of influenza A virus to the inhibitory effects of 2-deoxy-2,3-dehydro-N-trifluoroacetylneu-raminic acid (FANA). Virology 1975;63:98-104
   PubMedGoogle Scholar
• Campion K, Silagy CA, Keene O, et al. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998;352(9144):1877-81
   PubMedGoogle Scholar
• Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999;282(13):1240-6
   PubMed Web of Science ®Google Scholar
• Burnham AJ, Baranovich T, Govorkova EA. Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance. Antiviral Res 2013;100(2):520-34
   PubMed Web of Science ®Google Scholar
• Farrukee R, Mosse J, Hurt AC. Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses. Expert Rev Anti Infect Ther 2013;11(11):1135-45
   PubMed Web of Science ®Google Scholar
• Burch J, Paulden M, Conti S, et al. Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation. Health Technol Assess 2009;13:1-265
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000;283:1016-24
   PubMed Web of Science ®Google Scholar
• Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003;163:1667-72
   PubMed Web of Science ®Google Scholar
• Hernan MA, Lipsitch M. Oseltamivir and risk of lower respiratory complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis 2011;53:277-9
   PubMed Web of Science ®Google Scholar
• Von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993;363(6428):418-23
   PubMed Web of Science ®Google Scholar
• Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008;52(9):3284-92
   PubMed Web of Science ®Google Scholar
• Samson M, Abed Y, Desrochers FM, et al. Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir. Antimicrob Agents Chemother 2014;58(9):5220-8
   PubMedGoogle Scholar
• Cheng VC, To KK, Tse H, et al. Two years after pandemic influenza A/2009/H1N1: what have we learned? Clin Microbiol Rev 2012;25(2):223-63
   PubMed Web of Science ®Google Scholar
• Davies BE. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother 2010;65(Suppl 2):ii5-ii10
   PubMed Web of Science ®Google Scholar
• Louie JK, Yang S, Samuel MC, et al. Neuraminidase inhibitors for critically ill children with influenza. Pediatrics 2013;132(6):e1539-45
   Google Scholar
• Sugaya N, Kohno S, Ishibashi T, et al. Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. Antimicrob Agents Chemother 2012;56(1):369-77
   PubMed Web of Science ®Google Scholar
• Feng E, Ye D, Li J, et al. Recent advances in neuraminidase inhibitor development as anti-influenza drugs. Chem Med Chem 2012;7(9):1527-36
   Google Scholar
• Kitano M, Itoh Y, Kodama M, et al. Efficacy of single intravenous injection of peramivir against influenza B virus infection in ferrets and cynomolgus macaques. Antimicrob Agents Chemother 2011;55(11):4961-70
   PubMed Web of Science ®Google Scholar
• Boltz DA, Ilyushina NA, Arnold CS, et al. Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice. Antiviral Res 2008;80(2):150-7
   PubMedGoogle Scholar
• Babu YS, Chand P, Bantia S, et al. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem 2000;43(19):3482-6
   PubMed Web of Science ®Google Scholar
• Kohno S, Kida H, Mizuguchi M, et al. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob Agents Chemother 2011;55(6):2803-12
   PubMed Web of Science ®Google Scholar
• Hernandez JE, Adiga R, Armstrong R, et al. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States. Clin Infect Dis 2011;52(6):695-706
   PubMed Web of Science ®Google Scholar
• Yamashita M, Tomozawa T, Kakuta M, et al. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 2009;53(1):186-92
   PubMed Web of Science ®Google Scholar
• Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamiviroctanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother 2010;54(6):2575-82
   PubMed Web of Science ®Google Scholar
• Watanabe A, Chang SC, Kim MJ, et al. Long-acting neuraminidase inhibitor laninamiviroctanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, non inferiority clinical trial. Clin Infect Dis 2010;51(10):1167-75
   PubMed Web of Science ®Google Scholar
• Biota. Available from: http://investors.biotapharma.com/releasedetail.cfm?releaseid=863626
   Google Scholar
• Hurt AC, Butler J, Kelso A, Barr IG. Influenza antivirals and resistance: the next 10 years? Expert Rev Anti Infect Ther 2012;10(11):1221-3
   PubMed Web of Science ®Google Scholar
• McKimm-Breschkin JL. Resistance of influenza viruses to neuraminidase inhibitors – a review. Antiviral Res 2000;47(1):1-17
   PubMedGoogle Scholar
• Lackenby A, Hungnes O, Dudman SG, et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill 2008;13:8026
   PubMedGoogle Scholar
• Sheu T, Deyde V, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008;52:3284-92
   PubMed Web of Science ®Google Scholar
• Kourti A, Spanakos G, Politi L, Stavropoulou A, et al. Oseltamivir-resistant influenza A(H1N1) 2009 virus in Greece during the post pandemic 2010–2011 season. Int J Antimicrob Agents 2012;40(1):72-4
   Google Scholar
• Renaud C, Kuypers J, Englund JA. Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1. J Clin Virol 2011;52:70-8
   PubMed Web of Science ®Google Scholar
• Ison MG. Clinical use of approved influenza antivirals: therapy and prophylaxis. Influenza Other Respir Viruses 2013;7(Suppl 1):7:13
   PubMed Web of Science ®Google Scholar
• Hurt AC1, Holien JK, Parker M, et al. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virol 2009;83(20):10366-73
   PubMed Web of Science ®Google Scholar
• Gubareva LV, Matrosovich MN, Brenner MK, et al. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998;178:1257-62
   PubMed Web of Science ®Google Scholar
• Ferraris O, Kessler N, Lina B. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antiviral Res 2005;68(1):43-8
   PubMedGoogle Scholar
• Mont AS, McKimm-Breschkin JL, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006;50:2395-402
   PubMedGoogle Scholar
• Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004;364(9436):759-65
   PubMed Web of Science ®Google Scholar
• Escuret V, Frobert E, Bouscambert-Duchamp M, et al. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. J Clin Virol 2008;41:25-8
   PubMed Web of Science ®Google Scholar
• Baz M, Abed Y, Simon P, et al. Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses. J Infect Dis 2010;201(5):740-5
   PubMed Web of Science ®Google Scholar
• Meijer A, Lackenby A, Hungnes O, et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis 2009;15(4):552-60
   PubMed Web of Science ®Google Scholar
• Dharan NJ, Gubareva LV, Meyer JJ, et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009;301(10):1034-41
   PubMedGoogle Scholar
• Hurt AC, Ernest J, Deng YM, et al. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res 2009;83(1):90-3
   PubMedGoogle Scholar
• Besselaar TG, Naidoo D, Buys A, et al. Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa. Emerg Infect Dis 2008;14(11):1809-10
   PubMedGoogle Scholar
• Ciancio BC, Meerhoff TJ, Kramarz P, et al. Oseltamivir-resistant influenza A(H1N1) viruses detected in Europe during season 2007-8 had epidemiologic and clinical characteristics similar to co-circulating susceptible A(H1N1) viruses. Euro Surveill 2009;14:46
   Google Scholar
• Gooskens J, Jonges M, Claas EC, et al. Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus. JAMA 2009;301:1042-6
   PubMedGoogle Scholar
• CDC. Update: influenza activity–United States, September 28, 2008-April 4, 2009, and composition of the 2009–2010 influenza vaccine. MMWR Morb Mortal Wkly Rep 2009;58:369-74
   PubMedGoogle Scholar
• Baranovich T, Saito R, Suzuki Y. Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008–2009 season. J Clin Virol 2010;47:23-8
   PubMedGoogle Scholar
• Hauge SH, Dudman S, Borgen K, et al. Oseltamivir-resistant influenza viruses A (H1N1), Norway 2007–08. Emerg Infect Dis 2009;15:155-62
   PubMed Web of Science ®Google Scholar
• ECDC. Available from: http://ecdc.europa.eu/en/publications/Publications/110906_TER_Rapid_RiskAssessmentOseltamivir-resistantinfluenzaA.pdf
   Google Scholar
• Oseltamivir-resistant pandemic (H1N1) 2009 influenza virus, October 2009. Wkly Epidemiol Rec 2009;84:453-9
   PubMedGoogle Scholar
• Bloom JD1, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 2010;328(5983):1272-5
   PubMed Web of Science ®Google Scholar
• Abed Y, Pizzorno A, Bouhy X, Boivin G. Role of permissive neuraminidase mutations in influenza A/Brisbane/59/2007-like (H1N1) viruses. PLoS Pathog 2011;7:e1002431
   Google Scholar
• Wu NC, Young AP, Dandekar S, et al. Systematic identification of H274Y compensatory mutations in influenza A virus neuraminidase by high-throughput screening. J Virol 2013;87(2):1193-9
   PubMed Web of Science ®Google Scholar
• CDC. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5815a5.htm
   Google Scholar
• Chan M. World now at the start of 2009 influenza pandemic. WHO; Geneva, Switzerland: 2009
   Google Scholar
• Bauer K, Dürrwald R, Schlegel M, et al. Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008. Med Microbiol Immunol 2012;201(1):61-72
   PubMed Web of Science ®Google Scholar
• Sullivan SJ, Jacobson RM, Dowdle WR, Poland GA. (H1N1) 2009 influenza. Mayo Clin Proc 2010;85(1):64-76
   PubMed Web of Science ®Google Scholar
• WHO. Update on oseltamivir resistant pandemic (H1N1) 2009 influenza virus. Wkly Epidemiol Rec 2010;85:37-48
   Google Scholar
• Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009;325(5937):197-201
   PubMed Web of Science ®Google Scholar
• Hurt AC, Chotpitayasunondh T, Cox NJ, et al. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis 2012;12(3):240-8
   PubMed Web of Science ®Google Scholar
• CDC. Available from: www.cdc.gov/flu/weekly/weeklyarchives2010-2011/10-11summary.htm
   Google Scholar
• Renaud C, Kuypers J, Englund JA. Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1. J Clin Virol 2011;52:70-8
   PubMed Web of Science ®Google Scholar
• Storms AD, Gubareva LV, Su S, et al. Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11. Emerg Infect Dis 2012;18:308-11
   PubMed Web of Science ®Google Scholar
• Hurt AC, Hardie K, Wilson NJ, et al. Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N Engl J Med 2011;26:2541-2
   Google Scholar
• Graitcer SB, Gubareva L, Kamimoto L, et al. Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States. Emerg Infect Dis 2011;17:255-7
   PubMedGoogle Scholar
• Hurt AC, Deng YM, Ernest J, et al. Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1)2009 pandemic in the Asia-Pacific region, March 2009 to March 2010. Euro Surveill 2011;16(3):4
   Google Scholar
• Speers DJ, Williams SH, Pinder M, et al. Oseltamivir-resistant pandemic (H1N1) 2009 influenza in a severely ill patient: the first Australian case. Med J Australia 2010;192(3):166-8
   PubMedGoogle Scholar
• Wang B, Dwyer DE, Blyth CC, et al. Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections. Antiviral Res 2010;87(1):16-21
   PubMedGoogle Scholar
• Tramontana AR, George B, Hurt AC, et al. Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis 2010;16(7):1068-75
   PubMedGoogle Scholar
• Whitley RJ, Boucher CA, Lina B, et al. Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS). Clin Infect Dis 2013;56(9):1197-205
   PubMedGoogle Scholar
• Centers for Disease Control Prevention. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis–North Carolina, 2009. MMWR Morb Mortal Wkly Rep 2009;58:969-72
   PubMedGoogle Scholar
• Centers for Disease Control Prevention. Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients – Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep 2009;58:893-6
   PubMedGoogle Scholar
• Baz M, Abed Y, Papenburg J, et al. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N Engl J Med 2009;361:2296-7
   PubMed Web of Science ®Google Scholar
• ECDC. Public health development: oseltamivir-resistant pandemic (H1N1) 2009 influenza virus. 2009
   Google Scholar
• Meijer A, Jonges M, Abbink F, et al. Oseltamivir-resistant pandemic A(H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands, 2009-2010. Antiviral Res 2011;92(1):81-9
   PubMedGoogle Scholar
• CDC. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis – North Carolina, 2009. MMWR Morb Mortal Wkly Rep 2009;58(35):969-72
   PubMedGoogle Scholar
• HPA. HPA statement on possible transmission of oseltamivir resistant pandemic influenza A(H1N1). 2009
   Google Scholar
• Lackenby A, Moran Gilad J, Pebody R, et al. Continued emergence and changing epidemiology of oseltamivir-resistant influenza (H1N1)2009 virus, United Kingdom, winter 2010/11. Euro Surveill 2011;16:5
   Google Scholar
• Le QM, Wertheim HF, Tran ND, et al. Vietnam H1N1 Investigation Team. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N Engl J Med 2010;362(1):86-7
   PubMed Web of Science ®Google Scholar
• Meijer A, Jonges M, van Beek P, et al. Oseltamivir-resistant influenza A(H1N1)pdm09 virus in Dutch travellers returning from Spain, August 2012. Euro Surveill 2012;17(36):20266
   PubMedGoogle Scholar
• Leang SK, Deng YM, Shaw R, et al. Influenza antiviral resistance in the Asia-Pacific region during 2011. Antiviral Res 2013;97(2):206-10
   PubMed Web of Science ®Google Scholar
• Hurt AC, Hardie K, Wilson NJ, et al. Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. J Infect Dis 2012;206:148-57
   PubMed Web of Science ®Google Scholar
• Wang B, Taylor J, Ratnamohan M, et al. Frequency of oseltamivir resistance in Sydney, during the Newcastle outbreak of community transmitted oseltamivir-resistant influenza A(H1N1)pdm09 virus, Australia, June to August 2011. Euro Surveill 2012;17(27; pii: 20210
   Google Scholar
• CDC. Available from: www.cdc.gov/flu/weekly/weeklyarchives2011-2012/weekly51.htm
   Google Scholar
• ECDC. Available from: www.ecdc.europa.eu/en/publications/Publications/111230_SUR_Weekly_Influenza_Surveillance_Overview.pdf
   Google Scholar
• CDC. Available from: www.cdc.gov/flu/about/qa/antiviralresistance.htm
   Google Scholar
• CDC. CDC influenza division key points. 2014
   Google Scholar
• CDC. Available from: www.cdc.gov/flu/weekly/summary.htm
   Google Scholar
• Rameix-Welti MA, Munier S, Le Gal S, et al. Neuraminidase of 2007-2008 influenza A(H1N1) viruses shows increased affinity for sialic acids due to the D344N substitution. Antivir Ther 2011;16:597-60
   PubMedGoogle Scholar
• Woods CJ, Malaisree M, Pattarapongdilok N, et al. Long time scale GPU dynamics reveal the mechanism of drug resistance of the dual mutant I223R/H275Y neuraminidase from H1N1-2009 influenza virus. Biochemistry 2012;51(21):4364-75
   PubMedGoogle Scholar
• Van der Vries E, Stelma FF, Boucher CA. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med 2010;363(14):1381-2
   PubMed Web of Science ®Google Scholar
• Nguyen HT, Fry AM, Loveless PA, et al. Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin Infect Dis 2010;51(8):983-4
   PubMedGoogle Scholar
• Hurt AC, Lee RT, Leang SK, et al. Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro Surveill 2011;16(23):1
   Google Scholar
• Dapat C, Suzuki Y, Saito R, et al. Rare influenza A (H3N2) variants with reduced sensitivity to antiviral drugs. Emerg Infect Dis 2010;16:493-6
   PubMed Web of Science ®Google Scholar
• Oakley AJ, Barrett S, Peat TS, et al. Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. J Med Chem 2010;53(17):6421-31
   PubMedGoogle Scholar
• Russell RJ, Haire LF, Stevens DJ, et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006;443(7107):454-9
   Google Scholar
• Thorlund K, Awad T, Boivin G, Thabane L. Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis 2011;11:134
   PubMed Web of Science ®Google Scholar
• Lackenby A, Thompson CI, Democratis J. The potential impact of neuraminidase inhibitor resistant influenza. Curr Opin Infect Dis 2008;21(6):626-38
   PubMed Web of Science ®Google Scholar
• Ferraris O, Lina B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J Clin Virol 2008;41(1):13-19
   PubMed Web of Science ®Google Scholar
• Aoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther 2007;12:603-16
   PubMed Web of Science ®Google Scholar
• Okomo-Adhiambo M, Demmler-Harrison GJ, Deyde VM, et al. Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob Agents Chemother 2010;54(5):1834-41
   PubMed Web of Science ®Google Scholar
• Yen HL, Herlocher LM, Hoffmann E, et al. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother 2005;49(10):4075-84
   PubMed Web of Science ®Google Scholar
• Abed Y, Baz M, Boivin G. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir Ther 2006;11:971-6
   PubMed Web of Science ®Google Scholar
• Gubareva LV. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res 2004;103:199-203
   PubMed Web of Science ®Google Scholar
• Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004;364:759-65
   PubMed Web of Science ®Google Scholar
• Monto AS, McKimm-Breschkin JL, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006;50:2395-402
   PubMed Web of Science ®Google Scholar
• Dapat C, Suzuki Y, Saito R, et al. Rare influenza A (H3N2) variants with reduced sensitivity to antiviral drugs. Emerg Infect Dis 2010;16(3):493-6
   PubMedGoogle Scholar
• de Jong JC, Claas EC, Osterhaus AD, et al. A pandemic warning? Nature 1997;389(6651):554
   PubMed Web of Science ®Google Scholar
• WHO. Available from: www.who.int/influenza/human_animal_interface/Influenza_Summary_IRA_HA_
   Google Scholar
• Lauerman J, Simison R. Seven Indonesian bird flu cases linked to patients. 2006
   Google Scholar
• The Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005;353:1374-85
   PubMedGoogle Scholar
• Le QM, Kiso M, Someya K, et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005;437:1108
   PubMed Web of Science ®Google Scholar
• Govorkova EA, Ilyushina NA, Bindumadhav MM, et al. Competitive fitness of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a Ferret model. J Virol 2010;84(16):8042-50
   PubMedGoogle Scholar
• Garcia-Sosa AT, Sild S, Maran U. Design of multi-binding-site inhibitors, ligand efficiency, and consensus screening of avian influenza H5N1 wild-type neuraminidase and of the oseltamivir-resistant H274Y variant. J Chem Inf Model 2008;48(10):2074-80
   PubMedGoogle Scholar
• Hurt AC, Holien JK, Barr IG. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob Agents Chemother 2009;53:4433-40
   PubMed Web of Science ®Google Scholar
• McKimm-Breschkin J, Barrett S, Pudjiatmoko P, et al. Screening neuraminidase inhibitor susceptibility of avian influenza isolates from SE Asia 2005-2009 identifies H5N1 I222 mutants with reduced oseltamivir sensitivity. XIV International Symposium on Respiratory Virus Infections; 23–26 March 2012; Istanbul, Turkey; The Macrae Foundation; p3
   Google Scholar
• Govorkova EA, Baranovich T, Seiler P, et al. Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002–2012 shows need for continued monitoring. Antiviral Res 2013;98(2):297-304
   PubMedGoogle Scholar
• Sugaya N, Mitamura K, Yamazaki M, et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 2007;44:197-202
   PubMed Web of Science ®Google Scholar
• Hatakeyama S, Sugaya N, Ito M, et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 2007;297(13):1435-42
   PubMed Web of Science ®Google Scholar
• Escuret V, Collins PJ, Casalegno JS, et al. Novel I221L Substitution in Neuraminidase Confers High-Level Resistance to Oseltamivir in Influenza B Viruses. J Infect Dis 2014; pii: jiu244. [Epub ahead of print]
   PubMedGoogle Scholar
• Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother 2008;52:3284-92
   PubMed Web of Science ®Google Scholar
• Sleeman K, Sheu TG, Moore Z, et al. Influenza B viruses with mutation in the neuraminidase active site, North Carolina, USA, 2010-11. Emerg Infect Dis 2011;17:2043-6
   PubMed Web of Science ®Google Scholar
• Higgins RR1, Beniprashad M, Chong-King E, et al. Recovery of influenza B virus with the H273Y point mutation in the neuraminidase active site from a human patient. J Clin Microbiol 2012;50(7):2500-2
   PubMedGoogle Scholar
• CDC. Available from: www.cdc.gov/flu/about/qa/antiviralresistance.htm
   Google Scholar
• Moscona A, McKimm-Breschkin J. News about influenza B drug resistance that cannot be ignored. JAMA 2007;297:1492-3
   PubMed Web of Science ®Google Scholar
• Uyeki TM, Cox NJ. Global concerns regarding novel influenza A (H7N9) virus infections. N Engl J Med 2013;368(20):1862-4
   PubMed Web of Science ®Google Scholar
• WHO risk assessment: Human infections with avian influenza A(H7N9) virus 27 June 2014. Available from: www.who.int/influenza/human_animal_interface/influenza_h7n9/riskassessment_h7n9_27june14.pdf?ua=1
   Google Scholar
• Ke Y, Wang Y, Liu S, et al. High severity and fatality of human infections with avian influenza A (H7N9) infection in China. Clin Infect Dis 2013;57(10):1506-7
   PubMedGoogle Scholar
• Lee SS, Wong NS, Leung CC. Exposure to avian influenza H7N9 in farms and wet markets. Lancet 2013;381(9880):1815
   PubMedGoogle Scholar
• Yu X, Jin T, Cui Y, et al. Influenza H7N9 and H9N2 viruses: coexistence in poultry linked to human H7N9 infection and genome characteristics. J Virol 2014;88(6):3423-31
   PubMed Web of Science ®Google Scholar
• Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013;368:1888-97
   PubMed Web of Science ®Google Scholar
• Hay AJ, Hayden FG. Oseltamivir resistance during treatment of H7N9 infection. Lancet 2013;381(9885):2230-2
   PubMed Web of Science ®Google Scholar
• Hai R, Schmolke M, Leyva-Grado VH, et al. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat Commun 2013;4:2854
   PubMed Web of Science ®Google Scholar
• Hu Y, Lu S, Song Z, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013;381(9885):2273-9
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Flu Activity & Surveillance. 2008-2009 Influenza Season Week 32 ending August 15 2009
   Google Scholar
• Thorlund K, Awad T, Boivin G, Thabane L. Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis 2011;11(1):134
   PubMedGoogle Scholar
• Han N, Liu X, Mu Y. Exploring the mechanism of zanamivir resistance in a neuraminidase mutant: a molecular dynamics study. PLoS One 2012;7(9):e44057
   Google Scholar
• CDC. Influenza Antiviral Medications: Summary for Clinicians. 2014
   Google Scholar
• Hurt AC, Holien JK, Parker M, et al. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virol 2009;83(20):10366-73
   PubMed Web of Science ®Google Scholar
• Leang SK, Kwok S, Sullivan SG, et al. Peramivir and laninamivir susceptibility of circulating influenza A and B viruses. Influenza Other Respir Viruses 2014;8(2):135-9
   PubMedGoogle Scholar